Canada-based Response Biomedical has announced the expiration of its existing Chinese distribution agreement for cardiovascular products with O&D Biotech with effect from 31 December 2013.

Response Biomedical and O&D Biotech have signed the Chinese distribution agreement in February 2011.

Currently, Response Biomedical is in discussions with O&D Biotech regarding signing a new agreement whereby O&D Biotech could continue to market the company’s cardiovascular products under their own brand labels and registrations. However, there can be no assurance that a new agreement will be executed.

Recently, Response Biomedical has entered into two agreements to distribute its cardiovascular portfolio of RAMP products with two new Chinese distributors.

Following the China Food and Drug Administration approval for the company’s RAMP branded cardiovascular Point of Care Testing portfolio, the company has signed the two agreements.

Response Biomedical CEO Jeff Purvin noted the company believes that its two newest distributors have the experience and reputation to successfully expand its coverage of the Chinese market.

"We are in the process of bringing on additional distributors in China and we hope to successfully enter into a new agreement with O&D, our valued distributor for many years. Together, these distributors should provide a stronger base for long term growth in China," Purvin added.